High-content screening technology for studying drug-induced hepatotoxicity in cell models

Archives of Toxicology

Volumn 89, Issue 7, 2015, Pages 1007-1022

  Tolosa, Laia ^a   Gómez Lechón, M José ^a,b   Donato, M Teresa ^a,b,c  

^a INSTITUTO DE INVESTIGACIÓN SANITARIA DEL HOSPITAL CLÍNICO SAN CARLOS IDISSC   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Drugs; Hepatotoxicity; High content screening; Mechanisms

Indexed keywords

DRUG; FLUORESCENT DYE;

CELL CULTURE; CELL FUNCTION; CHOLESTASIS; DRUG INDUCED DISEASE; DRUG SAFETY; GENOTOXICITY; HIGH CONTENT SCREENING; HUMAN; IMAGE ANALYSIS; LIPIDOSIS; LIVER TOXICITY; MICROSCOPY; MITOCHONDRION; MOLECULAR BIOLOGY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; STEATOSIS; TOXIC HEPATITIS; TOXICITY ASSAY; ANIMAL; DRUG DEVELOPMENT; DRUG EFFECTS; DRUG-INDUCED LIVER INJURY; HIGH THROUGHPUT SCREENING; LABORATORY AUTOMATION; LIVER; LIVER CELL; METABOLISM; PATHOLOGY; PROCEDURES; RISK ASSESSMENT; SYSTEM ANALYSIS; SYSTEMS BIOLOGY; TOXICITY TESTING;

ANIMALS; AUTOMATION, LABORATORY; CELLS, CULTURED; DRUG DISCOVERY; DRUG-INDUCED LIVER INJURY; HEPATOCYTES; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; LIVER; RISK ASSESSMENT; SYSTEMS BIOLOGY; SYSTEMS INTEGRATION; TOXICITY TESTS;

EID: 84930925098     PISSN: 03405761     EISSN: 14320738     Source Type: Journal    
DOI: 10.1007/s00204-015-1503-z     Document Type: Review

References (82)

1. Abraham VC, Taylor DL, Haskins JR (2004) High content screening applied to large-scale cell biology. Trends Biotechnol 22:15–22. doi:10.1016/j.tibtech.2003.10.012
2. Abraham VC, Towne DL, Waring JF, Warrior U, Burns DJ (2008) Application of a high-content multiparameter cytotoxicity assay to prioritize compounds based on toxicity potential in humans. J Biomol Screen 13(6):527–537. doi:10.1177/1087057108318428
3. Amacher DE, Chalasani N (2014) Drug-induced hepatic steatosis. Semin Liver Dis 34(2):205–214. doi:10.1055/s-0034-1375960
4. Amacher DE, Martin BA (1997) Tetracycline-induced steatosis in primary canine hepatocyte cultures. Fundam Appl Toxicol 40(2):256–263. doi:10.1093/toxsci/40.2.256
5. Anguissola S, Garry D, Salvati A, O’Brien PJ, Dawson KA (2014) High content analysis provides mechanistic insights on the pathways of toxicity induced by amine-modified polystyrene nanoparticles. PLoS One 9(9):e108025. doi:10.1371/journal.pone.0108025
6. Antherieu S, Rogue A, Fromenty B, Guillouzo A, Robin MA (2011) Induction of vesicular steatosis by amiodarone and tetracycline is associated with up-regulation of lipogenic genes in HepaRG cells. Hepatology 53(6):1895–1905. doi:10.1002/hep.24290
7. Apostolova N, Gomez-Sucerquia LJ, Moran A, Alvarez A, Blas-Garcia A, Esplugues JV (2010) Enhanced oxidative stress and increased mitochondrial mass during Efavirenz-induced apoptosis in human hepatic cells. Br J Pharmacol 160(8):2069–2084. doi:10.1111/j.1476-5381.2010.00866.x
8. Begriche K, Massart J, Robin MA, Borgne-Sanchez A, Fromenty B (2011) Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver. J Hepatol 54(4):773–794. doi:10.1016/j.jhep.2010.11.006
9. Benet M, Moya M, Donato MT, Lahoz A, Hervas D, Guzman C, Gomez-Lechon MJ, Castell JV, Jover R (2014) A simple transcriptomic signature able to predict drug-induced hepatic steatosis. Arch Toxicol 88(4):967–982. doi:10.1007/s00204-014-1197-7
10. Bhandari N, Figueroa DJ, Lawrence JW, Gerhold DL (2008) Phospholipidosis assay in HepG2 cells and rat or rhesus hepatocytes using phospholipid probe NBD-PE. Assay Drug Dev Technol 6(3):407–419. doi:10.1089/adt.2007.119
11. Bhatia SN, Ingber DE (2014) Microfluidic organs-on-chips. Nat Biotechnol 32(8):760–772. doi:10.1038/nbt.2989
12. Bhise NS, Ribas J, Manoharan V, Zhang YS, Polini A, Massa S, Dokmeci MR, Khademhosseini A (2014) Organ-on-a-chip platforms for studying drug delivery systems. J Control Release 190:82–93. doi:10.1016/j.jconrel.2014.05.004
13. Bhushan A, Senutovitch N, Bale SS, McCarty WJ, Hegde M, Jindal R, Golberg I, Berk Usta O, Yarmush ML, Vernetti L, Gough A, Bakan A, Shun TY, DeBiasio R, Lansing Taylor D (2013) Towards a three-dimensional microfluidic liver platform for predicting drug efficacy and toxicity in humans. Stem Cell Res Ther 4(Suppl 1):S16. doi:10.1186/scrt377
14. Buchser W, Collins M, Garyantes T, Guha R, Haney S, Lemmon V, Li Z, Trask OJ (2004) Assay development guidelines for image-based high content screening, high content analysis and high content imaging. In: Assay guidance manual [Internet]. Eli Lilly & Company and the National Center for Advancing Translational Sciences, Bethesda, MD
15. Chen M, Tung CW, Shi Q, Guo L, Shi L, Fang H, Borlak J, Tong W (2014) A testing strategy to predict risk for drug-induced liver injury in humans using high-content screen assays and the ‘rule-of-two’ model. Arch Toxicol 88(7):1439–1449. doi:10.1007/s00204-014-1276-9
16. Cole SD, Madren-Whalley JS, Li AP, Dorsey R, Salem H (2014) High content analysis of an in vitro model for metabolic toxicity: results with the model toxicants 4-aminophenol and cyclophosphamide. J Biomol Screen 19(10):1402–1408. doi:10.1177/1087057114550399
17. Cosgrove BD, King BM, Hasan MA, Alexopoulos LG, Farazi PA, Hendriks BS, Griffith LG, Sorger PK, Tidor B, Xu JJ, Lauffenburger DA (2009) Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity. Toxicol Appl Pharmacol 237(3):317–330. doi:10.1016/j.taap.2009.04.002
18. Dambach DM, Andrews BA, Moulin F (2005) New technologies and screening strategies for hepatotoxicity: use of in vitro models. Toxicol Pathol 33(1):17–26
19. Dawson S, Stahl S, Paul N, Barber J, Kenna JG (2012) In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans. Drug Metab Dispos 40(1):130–138. doi:10.1124/dmd.111.040758
20. Diaz D, Scott A, Carmichael P, Shi W, Costales C (2007) Evaluation of an automated in vitro micronucleus assay in CHO-K1 cells. Mutat Res 630(1–2):1–13. doi:10.1016/j.mrgentox.2007.02.006
21. Donato MT, Gomez-Lechon MJ (2012) Drug-induced liver steatosis and phospholipidosis: cell-based assays for early screening of drug candidates. Curr Drug Metab 13(8):1160–1173. doi:10.2174/138920012802850001
22. Donato MT, Martinez-Romero A, Jimenez N, Negro A, Herrera G, Castell JV, O’Connor JE, Gomez-Lechon MJ (2009) Cytometric analysis for drug-induced steatosis in HepG2 cells. Chem Biol Interact 181(3):417–423. doi:10.1016/j.cbi.2009.07.019
23. Donato MT, Tolosa L, Jimenez N, Castell JV, Gomez-Lechon MJ (2012) High-content imaging technology for the evaluation of drug-induced steatosis using a multiparametric cell-based assay. J Biomol Screen 17(3):394–400. doi:10.1177/1087057111427586
24. Dykens JA, Jamieson JD, Marroquin LD, Nadanaciva S, Xu JJ, Dunn MC, Smith AR, Will Y (2008) In vitro assessment of mitochondrial dysfunction and cytotoxicity of nefazodone, trazodone, and buspirone. Toxicol Sci 103(2):335–345. doi:10.1093/toxsci/kfn056
25. Feng B, Xu JJ, Bi YA, Mireles R, Davidson R, Duignan DB, Campbell S, Kostrubsky VE, Dunn MC, Smith AR, Wang HF (2009) Role of hepatic transporters in the disposition and hepatotoxicity of a HER2 tyrosine kinase inhibitor CP-724,714. Toxicol Sci 108(2):492–500. doi:10.1093/toxsci/kfp033
26. Fujimura H, Murakami N, Kurabe M, Toriumi W (2009) In vitro assay for drug-induced hepatosteatosis using rat primary hepatocytes, a fluorescent lipid analog and gene expression analysis. J Appl Toxicol 29(4):356–363. doi:10.1002/jat.1420
27. Garside H, Marcoe KF, Chesnut-Speelman J, Foster AJ, Muthas D, Kenna JG, Warrior U, Bowes J, Baumgartner J (2014) Evaluation of the use of imaging parameters for the detection of compound-induced hepatotoxicity in 384-well cultures of HepG2 cells and cryopreserved primary human hepatocytes. Toxicol in Vitro 28(2):171–181. doi:10.1016/j.tiv.2013.10.015
28. Germano D, Uteng M, Pognan F, Chibout SD, Wolf A (2014) Determination of liver specific toxicities in rat hepatocytes by high content imaging during 2-week multiple treatment. Toxicol in Vitro. doi:10.1016/j.tiv.2014.05.009
29. Giuliano KA, Haskins JR, Taylor DL (2003) Advances in high content screening for drug discovery. Assay Drug Dev Technol 1(4):565–577. doi:10.1089/154065803322302826
30. Gomez-Lechon MJ, Lahoz A, Gombau L, Castell JV, Donato MT (2010) In vitro evaluation of potential hepatotoxicity induced by drugs. Curr Pharm Des 16(17):1963–1977. doi:10.2174/138161210791208910
31. Hartung T, Luechtefeld T, Maertens A, Kleensang A (2013) Integrated testing strategies for safety assessments. ALTEX 30(1):3–18
32. Hill A, Mesens N, Steemans M, Xu JJ, Aleo MD (2012) Comparisons between in vitro whole cell imaging and in vivo zebrafish-based approaches for identifying potential human hepatotoxicants earlier in pharmaceutical development. Drug Metab Rev 44(1):127–140. doi:10.3109/03602532.2011.645578
33. Igoudjil A, Massart J, Begriche K, Descatoire V, Robin MA, Fromenty B (2008) High concentrations of stavudine impair fatty acid oxidation without depleting mitochondrial DNA in cultured rat hepatocytes. Toxicol in Vitro 22(4):887–898. doi:10.1016/j.tiv.2008.01.011
34. Inglese J, Johnson RL, Simeonov A, Xia M, Zheng W, Austin CP, Auld DS (2007) High-throughput screening assays for the identification of chemical probes. Nat Chem Biol 3(8):466–479. doi:10.1038/nchembio.2007.17
35. Jan E, Byrne SJ, Cuddihy M, Davies AM, Volkov Y, Gun’ko YK, Kotov NA (2008) High-content screening as a universal tool for fingerprinting of cytotoxicity of nanoparticles. ACS Nano 2(5):928–938. doi:10.1021/nn7004393
36. Kasahara T, Tomita K, Murano H, Harada T, Tsubakimoto K, Ogihara T, Ohnishi S, Kakinuma C (2006) Establishment of an in vitro high-throughput screening assay for detecting phospholipidosis-inducing potential. Toxicol Sci 90(1):133–141. doi:10.1093/toxsci/kfj067
37. Kim JA, Han E, Eun CJ, Tak YK, Song JM (2012) Real-time concurrent monitoring of apoptosis, cytosolic calcium, and mitochondria permeability transition for hypermulticolor high-content screening of drug-induced mitochondrial dysfunction-mediated hepatotoxicity. Toxicol Lett 214(2):175–181. doi:10.1016/j.toxlet.2012.08.027
38. Labbe G, Pessayre D, Fromenty B (2008) Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies. Fundam Clin Pharmacol 22(4):335–353. doi:10.1111/j.1472-8206.2008.00608.x
39. LeCureux L, Cheng CS, Herbst J, Reilly TP, Lehman-McKeeman L, Otieno M (2011) Evaluation and validation of multiple cell lines and primary mouse macrophages to predict phospholipidosis potential. Toxicol in Vitro 25(8):1934–1943. doi:10.1016/j.tiv.2011.06.017
40. Marion TL, Leslie EM, Brouwer KL (2007) Use of sandwich-cultured hepatocytes to evaluate impaired bile acid transport as a mechanism of drug-induced hepatotoxicity. Mol Pharm 4(6):911–918. doi:10.1021/mp0700357
41. McBride HM, Neuspiel M, Wasiak S (2006) Mitochondria: more than just a powerhouse. Curr Biol 16(14):R551–R560. doi:10.1016/j.cub.2006.06.054
42. McMillian MK, Grant ER, Zhong Z, Parker JB, Li L, Zivin RA, Burczynski ME, Johnson MD (2001) Nile Red binding to HepG2 cells: an improved assay for in vitro studies of hepatosteatosis. In Vitro Mol Toxicol 14(3):177–190. doi:10.1089/109793301753407948
43. Miyamoto S, Matsumoto A, Mori I, Horinouchi A (2009) Relationship between in vitro phospholipidosis assay using HepG2 cells and 2-week toxicity studies in rats. Toxicol Mech Methods 19(8):477–485. doi:10.1080/15376510903322834
44. Nioi P, Perry BK, Wang EJ, Gu YZ, Snyder RD (2007) In vitro detection of drug-induced phospholipidosis using gene expression and fluorescent phospholipid based methodologies. Toxicol Sci 99(1):162–173. doi:10.1093/toxsci/kfm157
45. O’Brien PJ (2014) High-content analysis in toxicology: screening substances for human toxicity potential, elucidating subcellular mechanisms and in vivo use as translational safety biomarkers. Basic Clin Pharmacol Toxicol 115(1):4–17. doi:10.1111/bcpt.12227
46. O’Brien PJ, Irwin W, Diaz D, Howard-Cofield E, Krejsa CM, Slaughter MR, Gao B, Kaludercic N, Angeline A, Bernardi P, Brain P, Hougham C (2006) High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. Arch Toxicol 80(9):580–604. doi:10.1007/s00204-006-0091-3
47. Olson H, Betton G, Robinson D, Thomas K, Monro A, Kolaja G, Lilly P, Sanders J, Sipes G, Bracken W, Dorato M, Van Deun K, Smith P, Berger B, Heller A (2000) Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol 32(1):56–67. doi:10.1006/rtph.2000.1399
48. Pernelle K, Le Guevel R, Glaise D, Stasio CG, Le Charpentier T, Bouaita B, Corlu A, Guguen-Guillouzo C (2011) Automated detection of hepatotoxic compounds in human hepatocytes using HepaRG cells and image-based analysis of mitochondrial dysfunction with JC-1 dye. Toxicol Appl Pharmacol 254(3):256–266. doi:10.1016/j.taap.2011.04.018
49. Persson M, Loye AF, Mow T, Hornberg JJ (2013) A high content screening assay to predict human drug-induced liver injury during drug discovery. J Pharmacol Toxicol Methods 68(3):302–313. doi:10.1016/j.vascn.2013.08.001
50. Persson M, Loye AF, Jacquet M, Mow NS, Thougaard AV, Mow T, Hornberg JJ (2014) High-content analysis/screening for predictive toxicology: application to hepatotoxicity and genotoxicity. Basic Clin Pharmacol Toxicol 115(1):18–23. doi:10.1111/bcpt.12200
51. Pessayre D, Mansouri A, Berson A, Fromenty B (2010) Mitochondrial involvement in drug-induced liver injury. Handb Exp Pharmacol 196:311–365. doi:10.1007/978-3-642-00663-0_11
52. Pessayre D, Fromenty B, Berson A, Robin MA, Letteron P, Moreau R, Mansouri A (2012) Central role of mitochondria in drug-induced liver injury. Drug Metab Rev 44(1):34–87. doi:10.3109/03602532.2011.604086
53. Porceddu M, Buron N, Roussel C, Labbe G, Fromenty B, Borgne-Sanchez A (2012) Prediction of liver injury induced by chemicals in human with a multiparametric assay on isolated mouse liver mitochondria. Toxicol Sci. doi:10.1093/toxsci/KFS197
54. Ramirez CN, Antczak C, Djaballah H (2010) Cell viability assessment: toward content-rich platforms. Expert Opin Drug Discov 5(3):223–233. doi:10.1517/17460441003596685
55. Ranade AR, Wilson MS, McClanahan AM, Ball AJ (2014) High content imaging and analysis enable quantitative in situ assessment of CYP3A4 using cryopreserved differentiated HepaRG cells. J Toxicol 2014:291054. doi:10.1155/2014/291054
56. Rausch O (2006) High content cellular screening. Curr Opin Chem Biol 10(4):316–320. doi:10.1016/j.cbpa.2006.06.004
57. Reasor MJ, Hastings KL, Ulrich RG (2006) Drug-induced phospholipidosis: issues and future directions. Expert Opin Drug Saf 5(4):567–583. doi:10.1517/14740338.5.4.567
58. Schoonen WG, de Roos JA, Westerink WM, Debiton E (2005a) Cytotoxic effects of 110 reference compounds on HepG2 cells and for 60 compounds on HeLa, ECC-1 and CHO cells. II mechanistic assays on NAD(P)H, ATP and DNA contents. Toxicol in Vitro 19(4):491–503. doi:10.1016/j.tiv.2005.01.002
59. Schoonen WG, Westerink WM, de Roos JA, Debiton E (2005b) Cytotoxic effects of 100 reference compounds on Hep G2 and HeLa cells and of 60 compounds on ECC-1 and CHO cells. I mechanistic assays on ROS, glutathione depletion and calcein uptake. Toxicol in Vitro 19(4):505–516. doi:10.1016/j.tiv.2005.01.003
60. Schoonen WG, Stevenson JC, Westerink WM, Horbach GJ (2012) Cytotoxic effects of 109 reference compounds on rat H4IIE and human HepG2 hepatocytes. III: mechanistic assays on oxygen consumption with MitoXpress and NAD(P)H production with Alamar Blue. Toxicol in Vitro 26(3):511–525. doi:10.1016/j.tiv.2012.01.004
61. Schurdak ME, Vernetti LA, Abel SJ, Thiffault C (2007) Adaptation of an in vitro phospholipidosis assay to an automated image analysis system. Toxicol Mech Methods 17(2):77–86. doi:10.1080/15376510600860185
62. Shahane SA, Huang R, Gerhold D, Baxa U, Austin CP, Xia M (2014) Detection of phospholipidosis induction: a cell-based assay in high-throughput and high-content format. J Biomol Screen 19(1):66–76. doi:10.1177/1087057113502851
63. Shariff A, Kangas J, Coelho LP, Quinn S, Murphy RF (2010) Automated image analysis for high-content screening and analysis. J Biomol Screen 15(7):726–734. doi:10.1177/1087057110370894
64. Singh S, Carpenter AE, Genovesio A (2014) Increasing the Content of high-content screening: an overview. J Biomol Screen 19(5):640–650. doi:10.1177/1087057114528537
65. Stieger B, Fattinger K, Madon J, Kullak-Ublick GA, Meier PJ (2000) Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology 118(2):422–430. doi:10.1016/S0016-5085(00)70224-1
66. Swiss R, Niles A, Cali JJ, Nadanaciva S, Will Y (2013) Validation of a HTS-amenable assay to detect drug-induced mitochondrial toxicity in the absence and presence of cell death. Toxicol in Vitro 27(6):1789–1797. doi:10.1016/j.tiv.2013.05.007
67. Tait SW, Green DR (2012) Mitochondria and cell signalling. J Cell Sci 125(Pt 4):807–815. doi:10.1242/jcs.099234
68. Taylor DL (2010) A personal perspective on high-content screening (HCS): from the beginning. J Biomol Screen 15(7):720–725. doi:10.1177/1087057110374995
69. Tilmant K, Gerets HH, Dhalluin S, Hanon E, Depelchin O, Cossu-Leguille C, Vasseur P, Atienzar FA (2011) Comparison of a genomic and a multiplex cell imaging approach for the detection of phospholipidosis. Toxicol in Vitro 25(7):1414–1424. doi:10.1016/j.tiv.2011.04.010
70. Tolosa L, Donato MT, Perez-Cataldo G, Castell JV, Gomez-Lechon MJ (2012a) Upgrading cytochrome P450 activity in HepG2 cells co-transfected with adenoviral vectors for drug hepatotoxicity assessment. Toxicol in Vitro 26(8):1272–1277. doi:10.1016/j.tiv.2011.11.008
71. Tolosa L, Pinto S, Donato MT, Lahoz A, Castell JV, O’Connor JE, Gomez-Lechon MJ (2012b) Development of a multiparametric cell-based protocol to screen and classify the hepatotoxicity potential of drugs. Toxicol Sci 127(1):187–198. doi:10.1093/toxsci/kfs083
72. Tolosa L, Gomez-Lechon MJ, Perez-Cataldo G, Castell JV, Donato MT (2013) HepG2 cells simultaneously expressing five P450 enzymes for the screening of hepatotoxicity: identification of bioactivable drugs and the potential mechanism of toxicity involved. Arch Toxicol 87(6):1115–1127. doi:10.1007/s00204-013-1012-x
73. Tolosa L, Carmona A, Castell JV, Gomez-Lechon MJ, Donato MT (2014) High-content screening of drug-induced mitochondrial impairment in hepatic cells: effects of statins. Arch Toxicol. doi:10.1007/s00204-014-1334-3
74. Tsiper MV, Sturgis J, Avramova LV, Parakh S, Fatig R, Juan-Garcia A, Li N, Rajwa B, Narayanan P, Qualls CW Jr, Robinson JP, Davisson VJ (2012) Differential mitochondrial toxicity screening and multi-parametric data analysis. PLoS One 7(10):e45226. doi:10.1371/journal.pone.0045226
75. van de Water FM, Havinga J, Ravesloot WT, Horbach GJ, Schoonen WG (2011) High content screening analysis of phospholipidosis: validation of a 96-well assay with CHO-K1 and HepG2 cells for the prediction of in vivo based phospholipidosis. Toxicol in Vitro 25(8):1870–1882. doi:10.1016/j.tiv.2011.05.026
76. van Vliet E, Daneshian M, Beilmann M, Davies A, Fava E, Fleck R, Jule Y, Kansy M, Kustermann S, Macko P, Mundy WR, Roth A, Shah I, Uteng M, van de Water B, Hartung T, Leist M (2014) Current approaches and future role of high content imaging in safety sciences and drug discovery. ALTEX 31(4):479–493. doi:10.14573/altex.1405271
77. Westerink WM, Schirris TJ, Horbach GJ, Schoonen WG (2011) Development and validation of a high-content screening in vitro micronucleus assay in CHO-k1 and HepG2 cells. Mutat Res 724(1–2):7–21. doi:10.1016/j.mrgentox.2011.05.007
78. Xu JJ, Diaz D, O’Brien PJ (2004) Applications of cytotoxicity assays and pre-lethal mechanistic assays for assessment of human hepatotoxicity potential. Chem Biol Interact 150(1):115–128
79. Xu JJ, Henstock PV, Dunn MC, Smith AR, Chabot JR, de Graaf D (2008) Cellular imaging predictions of clinical drug-induced liver injury. Toxicol Sci 105(1):97–105. doi:10.1093/toxsci/kfn109
80. Xu JJ, Dunn MC, Smith AR, Tien ES (2012) Assessment of hepatotoxicity potential of drug candidate molecules including kinase inhibitors by hepatocyte imaging assay technology and bile flux imaging assay technology. Methods Mol Biol 795:83–107. doi:10.1007/978-1-61779-337-0_6
81. Ye N, Qin J, Shi W, Liu X, Lin B (2007) Cell-based high content screening using an integrated microfluidic device. Lab Chip 7(12):1696–1704. doi:10.1039/b711513j
82. Zock JM (2009) Applications of high content screening in life science research. Comb Chem High Throughput Screen 12(9):870–876